Study of ARC-520 in Participants With Hepatitis B Virus e Antigen (HBeAg) Positive Chronic Hepatitis B Virus

Phase 2 Terminated 4 enrolled Arrowhead Pharmaceuticals

RandomizedParallel-groupTriple-blindTreatment

Summary

Participants with chronic HBV infection will receive multiple doses of ARC-520 in combination with entecavir or tenofovir and be evaluated for safety and efficacy.

Timeline

Start: 2015-08
Primary completion: 2016-12
Completion: 2016-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	ARC-520	Unknown	1 mg/kg	Intravenous
Background	Diphenhydramine	Unknown	50 mg	Oral
Background	Entecavir	Small molecule	0.5 mg	Oral
Background	Entecavir	Small molecule	1 mg	Oral
Background	Tenofovir	Small molecule	300 mg	Oral

Study of ARC-520 in Participants With Hepatitis B Virus e Antigen (HBeAg) Positive Chronic Hepatitis B Virus

Summary

Timeline

Drugs

Indications